Update on cardiovascular disease in lupus

Area of Science:

• Immunology
• Cardiovascular Science
• Rheumatology

Background:

• Atherosclerotic cardiovascular disease (ASCVD) causes significant mortality in systemic lupus erythematosus (SLE) patients.
• Traditional cardiovascular risk factors do not fully explain the elevated ASCVD risk in SLE.
• Emerging immunologic pathways in SLE are implicated in accelerated atherosclerosis.

Purpose of the Study:

• To review the immunologic underpinnings of accelerated atherosclerosis in SLE.
• To identify how aberrant immune responses in SLE contribute to cardiovascular disease.
• To highlight potential therapeutic targets for managing ASCVD in SLE patients.

Main Methods:

• Review of recent immunologic discoveries related to SLE and atherosclerosis.
• Analysis of innate and adaptive immune responses in lupus pathogenesis.
• Examination of specific cellular and molecular pathways involved in endothelial dysfunction and plaque progression.

Main Results:

• Aberrant immune responses in SLE, including defective apoptosis and dysregulated type I interferon, contribute to endothelial dysfunction.
• SLE macrophages exhibit an inflammatory phenotype that promotes atherosclerotic plaque progression.
• Autoantibodies, abnormal lipoprotein function, and neutrophil responses are implicated.

Conclusions:

• Immune dysregulation in SLE plays a critical role in accelerated atherosclerosis.
• Targeting specific immune pathways may reduce cardiovascular risk and improve outcomes in SLE patients.
• Further research into the immunology of ASCVD in SLE is warranted for developing novel therapies.